| First Posted | New Trial Filing | Phase | Status |
|---|---|---|---|
| 2026-05-27 | NCT07609121 Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable… | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT07357623 | Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary… | Pulmonary Neuroendocrine Tumor | Recruiting |
| NCT07469956 | Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk… | Pancreatic Cancer Resectable | Not Yet Recruiting |
| NCT07609121 | Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable… | NSCLC (Non-small Cell Lung Cancer) | Not Yet Recruiting |
| NCT05106777 | Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma | Sarcoma | Active, Not Recruiting |
| Not specified | |||
| NCT07534371 | Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in… | Neuroendocrine Tumors | Active, Not Recruiting |